Ethionamide cross-and co-resistance in children with isoniazid-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 13, Issue 11, 2009, Pages 1355-1359

  Schaaf, H S ^a   Victor, T C ^b   Venter, A ^b   Brittle, W ^a   Jordaan, A M ^b   Hesseling, A C ^a   Marais, B J ^a   Van Helden, P D ^b   Donald, P R ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Children; Drug resistance; Ethionamide; Isoniazid; Tuberculosis

Indexed keywords

ETHIONAMIDE; ISONIAZID; BACTERIAL PROTEIN; CATALASE; INHA PROTEIN, MYCOBACTERIUM; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CHILD; CLINICAL ARTICLE; CROSS RESISTANCE; GENE MUTATION; HUMAN; INFANT; INHA GENE; KATG GENE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM; PEDIATRICS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROMOTER REGION; SOUTH AFRICA; TUBERCULOSIS; CASE CONTROL STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PHENOTYPE; PROSPECTIVE STUDY; TREATMENT FAILURE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CASE-CONTROL STUDIES; CATALASE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; ETHIONAMIDE; GENOTYPE; HUMANS; INFANT; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PHENOTYPE; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; SOUTH AFRICA; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 73949114583     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization, 2008.
2. Rist N, Grumbach F, Libermann D. Experiments on the anti-tuberculous activity of alpha-ethyl-thioisonicotinamide. Am Rev Tuberc 1959; 79: 1-5.
3. Baulard A R, Betts J C, Engohang-Ndong J, et al. Activation of the pro-drug ethionamide is regulated in mycobacteria. J Biol Chem 2000; 275: 28326-28331.
4. Schwartz W S. Comparison of ethionamide and isoniazid in the original treatment of pulmonary tuberculosis. Am Rev Respir Dis 1966; 93: 685-692.
5. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva, Switzerland: WHO, 2006.
6. Canetti G. Present aspects of bacterial resistance in tuberculosis. Am Rev Respir Dis 1965; 92: 687-703.
7. Bannerjee A, Dudnau E, Quenard A, et al. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994; 263: 227-230.
8. DeBarber A E, Mdluli K, Bosman M, Bekker L G, Barry C E III. Ethionamide activation and sensitivity in multidrug-r esistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000; 97: 9677-9682.
9. Morlock G P, Metchock B, Sikes D, Crawford J T, Cooksey R C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-3805.
10. Schaaf H S, Marais B J, Hesseling A C, Gie R P, Beyers N, Donald P R. Childhood drug-resistant tuberculosis in the Western Cape province of South Africa. Acta Paediatrica 2006; 95: 523-528.
11. Schaaf H S, Marais B J, Hesseling A C, Brittle W, Donald P R. Surveillance of anti-tuberculosis drug resistance amongst children from the Western Cape Province of South Africa\an upward trend. Am J Public Health 2009; 99: 1486-1490.
12. Schaaf H S, Victor T C, Engelke E, et al. Minimal inhibitory concentration of isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis 2007; 26: 203-205.
13. Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility testing of Mycobacte-rium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin Microb 1999; 37: 3179-3186.
14. Guo H, Seet Q, Denkin S, Parsons L, Zhang Y. Molecular characterization of isoniazid-resistant clinical isolates of Mycobac-terium tuberculosis from the USA. J Med Microbiol 2006; 55: 1527-1531.
15. Victor T C, Streicher E M, Kewley C, et al. Spread of an emerging Mycobacterium tuberculosis drug-resistant strain in the Western Cape of South Africa. Int J Tuberc Lung Dis 2006; 11: 195-201.
16. Edlin B R, Tokars J I, Grieco M G, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodef ciency syndrome. N Eng J Med 1992; 326: 1514-1521.
17. Frieden T R, Sherman L F, Maw K L, et al. A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes. JAMA 1996; 276: 1229-1235.
18. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1554-1556.
19. Rieder H L. Drug-resistant tuberculosis: issues in epidemiology and challenges for public health. Tubercle Lung Dis 1993; 75: 321-323.
20. Lee H, Cho S N, Bang H E, et al. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacte-rium tuberculosis isolates from Korea. Int J Tuberc Lung Dis 2000; 4: 441-447.
21. Johnson R, Streicher E M, Louw G E, Warren R M, van Helden P D, Victor T C. Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol 2006; 8: 97-111.
22. Zhang M, Yue J, Yang Y-P. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2005; 43: 5477-5482.
23. Lavender C, Globan M, Sievers A, Billman-Jacobe H, Fyfe J. Molecular characterization of Mycobacterium tuberculosis isoniazid-resistant isolates collected in Australia. Antimicrob Agents Chemother 2005; 49: 4068-4074.
24. González N, Torres M J, Aznar J, Palomares J C. Molecular analysis of rifampin and isoniazid resistance of Mycobacte-rium tuberculosis clinical isolates in Seville, Spain. Tubercle Lung Dis 1999; 79: 187-190.
25. Kiepiela P, Bishop K S, Smith A N, Roux L, York D F. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tubercle Lung Dis 2000; 80: 47-66.
26. Gagneux S, Burgos M V, DeRiemer K, et al. Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacte-rium tuberculosis. PLoS Pathog 2006; 2: e61
27. Department of Health, South Africa. Diagnosis of tuberculosis. In: The South African National Tuberculosis Control Programme practical guidelines 2004. Chapter 4. Pretoria, South Africa: Department of Health, 2005: pp 12-19.
28. Louw G E, Warren R M, Donald P R, Murray M B, Bosman M. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis 2006; 10: 802-807.
29. Katiyar S K, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008; 12: 139-145.